Vivian Trein Cunha

Mortality Reduction of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Heart Failure: An Updated Meta-Analysis. Does Recent Evidence Change the Standard of Care?

BACKGROUND The recent publication of the MADIT-CRT and RAFT trials has more than doubled the number of patients in which a direct comparison of the combination of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) versus ICD alone was carried out. The present meta-analysis aims to assess the impact of combined CRT and ICD therapy on survival of heart failure (HF) patients. METHODS AND RESULTS Medline, Embase, and the Cochrane Library databases were searched, and all randomized controlled trials of CRT alone or combined with ICDs in HF resulting from left ventricular systolic dysfunction were included. Main outcome was all-cause mortality. Summary relative risk (RR) and 95% confidence interval (CI) were calculated employing random-effects models. Twelve studies were included, with a total of 8,284 randomized patients. For the comparison of CRT alone versus medical therapy, pooled analysis of 5 available trials demonstrated a significant reduction in all-cause mortality with CRT (RR 0.76, 95% CI: 0.64-0.9). Pooled analysis of 6 trials that compared the combination of CRT and ICD therapy to ICD alone also showed a statistically significant reduction in all-cause mortality (RR 0.83, 95% CI: 0.72-0.96). Stratified analysis showed significant mortality reductions in all New York Heart Association class subgroups, with greater effect in classes III-IV (RR 0.70; 95% CI: 0.57-0.88). Pooled estimates of implant-related risks were 0.6% for death and 8% for implant failure. CONCLUSION Combined CRT and ICD therapy reduces overall mortality in HF patients when compared with ICD alone.

Three unreported glucokinase (GCK) missense mutations detected in the screening of thirty-two Brazilian kindreds for GCK and HNF1A-MODY

Thirty-two Brazilian families with MODY phenotype were screened for GCK and HNF1A mutations. GCK mutations were found in 8 families, all patients with mild asymptomatic hyperglycaemia; 3 of them are novel: p.Asp365Asn, p.Gly81Asp and p.Val253Leu. Previously described mutations in HNF1A were found in 2 families.

Cutaneous human immunodeficiency virus (HIV)‐associated lymphomatoid granulomatosis: complete regression following antiretroviral therapy

1 Lombeck T, Schnippering HG, Ritzl F, Bremer HJ, et al. Absorption of zinc in Acrodermatitis enteropathica. Lancet 1975; 1: 855. 2 Mortimer PS, Gough P, Newbold PC, et al. Acrodermatitis enteropathica. J R Soc Med 1984; 77: 67–68. 3 Donbolt N. Acrodermatitis enteropathica. Br J Dermatol 1979; 100: 37–40. 4 Wang F, Kim BE, Dufiner-Beattie J, et al. Acrodermatitis enterpathica mutations affect transport activity, localization and zinc-responsive trafficking of the mouse ZIP4 zinc transporter. Hum Mol Genet 2004; 13: 563–571. 5 Geiser J, Venken KJT, De Lisle RC, et al. A mouse model of Acrodermatitis enteropathica: loss of intestine zinc transporter ZIP4 (Slc39a4) disrupts the stem cell niche and intestine integrity. PLoS Genet 2012; 8: e1002766. 6 Schmitt S, K€ ury S, Giraud M, et al. An update on mutations of SLC39A4 gene in acrodermatitis euteropathica. Hum Mutat 2009; 30: 826–933. 7 Rodd F. Kahena, Queen of the Berbers: “A Sketch of the Arab Invasion of North Africa in the First Century of the Hijra. Bull Sch Orient Stud 1925; 3: 731–732.